<DOC>
	<DOCNO>NCT01053988</DOCNO>
	<brief_summary>The Purpose study ass efficacy safety two strength FF/GW642444 Inhalation Powder subject chronic obstructive pulmonary disease ( COPD )</brief_summary>
	<brief_title>A 6-month Study Evaluate Efficacy Safety Fluticasone Furoate ( FF ) /GW642444 Inhalation Powder Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Type subject : outpatient Informed consent : Subjects must give sign dated write informed consent participate . Gender : Male female subject A female eligible enter participate study : Nonchild bear potential OR Child bear potential , negative pregnancy test screening , agree one acceptable contraceptive method define protocol Age : ≥40 year age Screening ( Visit 1 ) COPD diagnosis : Subjects clinical history COPD accordance definition American Thoracic Society/European Respiratory Society [ Celli , 2004 ] Tobacco use : Subjects current prior history ≥10 packyears cigarette smoke Screening ( Visit 1 ) . Severity Disease : Subjects Screening ( Visit 1 ) measure postalbuterol/salbutamol : FEV1/FVC ratio ≤0.70 FEV1 ≤70 % predict normal value Dyspnea : Achieved score ≥2 Modified Medical Research Council Dyspnea Scale ( mMRC ) Screening ( Visit 1 ) . Subjects meet follow criterion must enrol study : Pregnancy : Women pregnant lactate plan become pregnant study . Asthma : Subjects current diagnosis asthma α1antitrypsin deficiency : Subjects α1antitrypsin deficiency underlie cause COPD Other respiratory disorder : Subjects active tuberculosis , lung cancer , bronchiectasis , sarcoidosis , lung fibrosis , pulmonary hypertension , interstitial lung disease , active pulmonary disease Lung resection : Subjects lung volume reduction surgery within 12 month prior Screening ( Visit 1 ) Chest Xray ( CT scan ) : Subjects chest Xray ( CT scan ) reveals evidence clinically significant abnormality believe due presence COPD . Hospitalization : Subjects hospitalize due poorly control COPD within 12 week Visit 1 . Poorly control COPD : Subjects poorly control COPD , define occurrence follow 6 week prior Visit 1 : Acute worsen COPD manage subject corticosteroid antibiotic require treatment prescribed physician . Lower respiratory tract infection : Subjects low respiratory tract infection require use antibiotic within 6 week prior Visit 1 . Other diseases/abnormalities : Subjects historical current evidence clinically significant cardiovascular ( i.e. , pacemaker ) , neurological , psychiatric , renal , hepatic , immunological , endocrine ( include uncontrolled diabetes thyroid disease ) haematological abnormality uncontrolled . Peptic Ulcer disease : Subjects clinically significant peptic ulcer disease uncontrolled . Hypertension : Subjects clinically significant hypertension uncontrolled . Cancer : Subjects carcinoma complete remission least 5 year . Carcinoma situ cervix , squamous cell carcinoma basal cell carcinoma skin would exclude subject consider cure within 5 year since diagnosis . Drug/food allergy : Subjects history hypersensitivity study medication component inhalation powder Drug/alcohol abuse : Subjects know suspected history alcohol drug abuse within last 2 year Medication prior spirometry : Subjects medically unable withhold albuterol/salbutamol and/or ipratropium 4 hour prior spirometry test study visit Additional medication : Use certain medication bronchodilator corticosteroid protocolspecified time prior Visit 1 ( Investigator discuss specific medication ) Oxygen therapy : Subjects receive treatment longterm oxygen therapy ( LTOT ) nocturnal oxygen therapy require great 12 hour day . Oxygen prn use ( i.e. , ≤12 hour per day ) exclusionary . Sleep apnea : Subjects clinically significant sleep apnea require use continuous positive airway pressure ( CPAP ) device noninvasive positive pressure ventilation ( NIPPV ) device . Pulmonary rehabilitation : Subjects participate acute phase Pulmonary Rehabilitation Program within 4 week prior Screening ( Visit 1 ) enter acute phase Pulmonary Rehabilitation Program study . Noncompliance : Subjects risk noncompliance , unable comply study procedure . Any infirmity , disability , geographic location would limit compliance schedule visit . Questionable validity consent : Subjects history psychiatric disease , intellectual deficiency , poor motivation condition limit validity inform consent participate study . Prior use study medication/other investigational drug Affiliation investigator site : Study investigator , subinvestigators , study coordinator , employee participate investigator immediate family member aforementioned excluded participating study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Efficacy</keyword>
	<keyword>FEV1</keyword>
	<keyword>COPD</keyword>
</DOC>